CG Oncology

cgoncology.com

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy that has shown clinical benefit in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). The company aims to provide innovative therapies that enhance the quality of life for urologic cancer patients, positioning itself as a leader in the bladder cancer treatment market with a strong focus on patient-centered care and ongoing clinical trials.